Published • loading... • Updated
Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets
INFARMED’s approval lets Tilray Medical conduct in-house testing, which it says will cut batch-release costs and shorten product timelines.
Summary by Globe Newswire
7 Articles
7 Articles
NiagaraFallsReview.ca+5 Reposted by 5 other sources
Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets
CANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulatory milestone…
·Niagara Falls, Canada
Read Full Article
INFARMED approves Tilray Medical laboratory for microbiological and physico-chemical tests, reinforcing the global supply chain of medicinal cannabis
Coverage Details
Total News Sources7
Leaning Left4Leaning Right1Center1Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
C 17%
R 16%
Factuality
To view factuality data please Upgrade to Premium
